posted on 2025-02-13, 12:03authored byTyler
B. Alt, Graham R. Moran
Human
ferroptosis suppressor protein 1 (HsFSP1) is an
NAD(P)H:quinone
oxidoreductase with broad substrate specificity that has been widely
implicated in aiding malignant neoplastic cell survival. FSP1 is myristoylated
and associated with membranes, where it regenerates the reduced forms
of quinones using electrons from NADPH. The quinol products intercept
reactive oxygen species and ameliorate lipid peroxidation, preventing
ferroptosis, a form of regulated cell death. While FSP1 enzymes have
been reported to have 6-OH-FAD as an active cofactor, aerobic titration
of the enzyme with NADPH in the presence and absence of ubiquinone
(UQ) reveals that this is more likely an artifact and that the native
form of HsFSP1 has unmodified FAD as the cofactor. Moreover, HsFSP1
suppresses the reaction of the reduced FAD with molecular oxygen three-fold
which, from a kinetic standpoint, severely limits the opportunity
for cofactor modification. The isolated form of the enzyme has NADP+ bound and the rate of release of this product limits the
observed rate of reduction by NAD(P)H molecules. The reduction of
substrate quinones occurs rapidly (≥2000 s–1), dictating that the rate of turnover is wholly defined by the rate
of release of NADP+ from the HsFSP1·NADP+ complex. Given that HsFSP1 does not distinguish ubiquinone from
ubiquinol by significant differences in binding affinity, this pronounced
catalytic commitment to quinone reduction serves to overcome presumed
kinetic limitations imposed by the abundance of ubiquinol relative
to ubiquinone in the membrane. This characteristic also maintains
the enzyme ostensibly fully in the oxidized state under turnover conditions,
preventing significant futile reduction of dioxygen.